Pricing Log in Create free account

Mineralys Therapeutics, Inc. (MLYS) vs Taysha Gene Therapies, Inc. (TSHA)

Mineralys Therapeutics, Inc. and Taysha Gene Therapies, Inc. are both Biotechnology companies. Mineralys Therapeutics, Inc. and Taysha Gene Therapies, Inc. are of similar size ($1.4B and $1.3B). Across the 9 metrics below, Taysha Gene Therapies, Inc. leads on 6 and Mineralys Therapeutics, Inc. on 3.

Valuation

Metric MLYS TSHA Biotechnology median
P/E n/m n/m 10.60
P/S n/m 136.10 9.40
P/B 2.36 4.15 2.13
Price to free cash flow n/m n/m 25.18
EV/EBITDA n/m n/m 0.66
EV/Sales n/m 101.67 9.02
Earnings yield (27.62%) (9.66%) (32.88%)
Free cash flow yield (10.68%) (8.66%) (23.13%)

Profitability

Metric MLYS TSHA Biotechnology median
Gross margin — 100.00% 68.51%
Operating margin 0.00% 0.00% 0.00%
Net margin 0.00% 0.00% 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity (80.88%) (47.05%) (51.96%)
Return on assets (69.67%) (37.23%) (46.06%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric MLYS TSHA Biotechnology median
Revenue growth (TTM) — 18.96% 6.76%
EPS growth (last fiscal year) 37.43% 5.56% 29.88%
Revenue growth, 5-year CAGR — — 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric MLYS TSHA Biotechnology median
Debt to equity 0.18 0.13 0.00
Current ratio 34.46 17.76 4.97
Net debt to EBITDA 3.85 2.47 1.01

Dividend

Metric MLYS TSHA Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric MLYS TSHA Biotechnology median
Market cap 1.35b 1.33b 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack